Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Advanced Medical Solutions Group EV-to-EBITDA?
Advanced Medical Solutions GroupCHIX:AMSL 92 EV-to-EBITDA is 15.27 as of Jul. 20, 2026, which is 14% below its 10-year median of 17.83. GuruFocus rates CHIX:AMSL with a GF Score™ of 92/100 and a GF Value™ of £3.72 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 54.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Advanced Medical Solutions Group's enterprise value is £671.8 Mil.
Advanced Medical Solutions Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £44.0 Mil. Therefore, Advanced Medical Solutions Group's EV-to-EBITDA for today is 15.27.
The historical rank and industry rank for Advanced Medical Solutions Group's EV-to-EBITDA or its related term are showing as below:
CHIX:AMSl'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.28 Med: 17.83 Max: 39.8
Current: 15.27
During the past 13 years, the highest EV-to-EBITDA of Advanced Medical Solutions Group was 39.80. The lowest was 9.28. And the median was 17.83.
CHIX:AMSl's EV-to-EBITDA is ranked worse than 54.9% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.155
vs CHIX:AMSl: 15.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Advanced Medical Solutions Group (CHIX:AMSl) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Advanced Medical Solutions Group's PE Ratio (TTM) for today is calculated as:
Advanced Medical Solutions Group's share price for today is £2.795.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Medical Solutions Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.045.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group EV-to-EBITDA Chart
CHIX:AMSL vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's EV-to-EBITDA falls into.
Advanced Medical Solutions Group's current Enterprise Value is £671.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Medical Solutions Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £44.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group (CHIX:AMSL) has a EV-to-EBITDA of 15.27 as of Jul. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Advanced Medical Solutions Group. This is 14% below median its historical median of 17.83. Over the past decade, Advanced Medical Solutions Group's EV-to-EBITDA has ranged from 9.28 to 39.80. According to the industry distribution chart, Advanced Medical Solutions Group ranks #280 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 54.9%.
Is Advanced Medical Solutions Group's EV-to-EBITDA too high?
Advanced Medical Solutions Group's current EV-to-EBITDA of 15.27 is 14% below median its 10-year median of 17.83. Over the past 10 years, this metric has ranged from a low of 9.28 to a high of 39.80. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.16. Advanced Medical Solutions Group's value of 15.27 is 7.9% above this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #280 out of 510 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #280 out of 510 companies for EV-to-EBITDA. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median EV-to-EBITDA is 14.16. Advanced Medical Solutions Group's value of 15.27 is 7.9% above this benchmark. Historically, Advanced Medical Solutions Group's own EV-to-EBITDA has ranged from 9.28 to 39.80 over the past decade. While the company's 10-year median is 17.83 vs. the industry median of 14.16, Advanced Medical Solutions Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.16, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current EV-to-EBITDA of 15.27 is 7.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Advanced Medical Solutions Group. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current EV-to-EBITDA is 15.27, which is 14% below median its own 10-year median of 17.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.72, compared to a current price of £2.80 — trading 24.9% below its estimated fair value. The current EV-to-EBITDA is 15.27, which is 14% below median its 10-year median of 17.83 and 7.9% above the Medical Devices & Instruments industry median of 14.16. Advanced Medical Solutions Group's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current EV-to-EBITDA is 15.27 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.80 is trading 24.9% below its estimated GF Value™ of £3.72.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
EV-to-EBITDA: 15.27 (14% below median its 10-year median of 17.83)
GF Value™: £3.72 vs. price of £2.80 (24.9% below fair value)
Industry Position: 7.9% above the Medical Devices & Instruments median (#280 of 510)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
92GF Score
Get the complete analysis for CHIX:AMSL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
